Pressure BioSciences, Inc. (PBIO) Receives Pivotal
Post# of 1354
(Total Views: 268)
Posted On: 08/14/2020 5:05:40 PM
Pressure BioSciences, Inc. (PBIO) Receives Pivotal U.S. Patent for Novel, High-Pressure Enhanced Consumable Device
- Pressure BioSciences develops and sells pressure-based instruments and consumables to the global life sciences, food and beverage, and other large research markets
- Their products are based on three key technology platforms, led by their proprietary Pressure Cycling Technology (“PCT”)
- The award of the PCT MicroPestle (“MP”) patent moves Pressure BioSciences even closer to entering the clinical diagnostics market, which is exponentially larger than the research products market where the Company currently transacts business
- The Company utilizes a “razor: razor blade” business model, and the PCT MP is the Company’s most important and popular consumable to date
- PBI has seen revenue from consumables steadily increase in recent years and double in just four years. The new patent provides greater security for its business model as well as potential for more explosive growth
- Recent publications from highly regarded scientists in Australia, China, and the U.S., cite the important use of PCT and the PCT MP in critical areas of scientific research, including cancer and COVID-19 research
Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide Life Sciences and other industries, has been awarded a pivotal U.S. patent for “Sample Preparation Devices and Methods” (http://nnw.fm/fIYe6).
With this new patent, the Company continues to expand its already significant intellectual property ownership, which now includes 25 issued patents.
Pressure BioSciences’ unique pressure cycling technology (“PCT”) systems are comprised of two major, interdependent components: the pressure cycling instrument and the consumable that contains and delivers the cycled pressure to the sample. The newly patented PCT MicroPestle (“MP”) is a critical addition to the Company’s impressive instruments and consumables product line.
The PCT MP is the Company’s most important and popular consumable to date, having a unique construction that seals and protects the sample while flexing to transfer immense pressures to the important samples being processed inside the MP tube. This, in turn, facilitates homogenization and precise physical and chemical preparation of biological samples, sometimes very small and hard-to-process specimens such as needle biopsies, small suspensions of cells, and laser micro-dissected tissue sections.
The PCT MicroPestle is designed with inert fluoropolymer material, which maintains stability for the sample as it experiences significant temperature fluctuations. The PCT MP also provides powerful resistance to aggressive chemicals. Extremely low surface binding characteristics enable the PCT MP to preserve and maximize the availability of each sample’s precious molecules, which often include important biomarkers for disease diagnosis or critical prognostic decisions regarding treatment selection and guidance.
Recent publications cite the use of PCT and the PCT MP in cancer and COVID-19 research, citing the use of the Company’s products in their studies to develop better methods for the detection, prevention, and cure of infectious diseases.
Prospective Financial Impact of the New Patent
With the PCT MP, Pressure BioSciences inches all that much closer to entering the clinical market, which has exponentially larger potential than the research market, where the Company currently transacts business. With just one proven clinical application of PCT and the PCT MP, Pressure BioSciences will have enormous potential for revenue.
PCT instruments tend to heavily impact revenue up front, while consumables continue to provide revenue potential throughout the life of the instrument. Pressure BioSciences has seen revenue from consumables steadily increase in recent years and double in just the past four years, from $150K in 2015 to $260K in 2017 and then $300K in 2019. The new patent provides even more security for this kind of growth and potential for more explosive growth.
Several high-profile labs in pharma, biotech, government, and academia routinely use the PCT MP. Publications about the capabilities of PCT MP are making their way into circulation and garnering attention. This is particularly true for the processing of minute cancer biopsy tissues and other small specimens where the options for a high-quality processing method are few and far between.
Worldwide Customer Demand
According to Ms. Roxana McCloskey, Pressure BioSciences’ Global Director of Sales and Marketing, the PCT MP is already used in prominent studies such as the one conducted by Professor Phil Robinson and his team at the Children’s Medical Research Institute in Australia (processing 70,000 tumor samples, looking for prognostic and diagnostic markers in cancer) and the one run by Dr. Tiannan Guo and his team at Westlake University in China (studying thyroid cancer and COVID-19).
The PCT MP is also a critical part of the innovative laser microdissection tumor processing workflow developed by Dr. Tom Conrads of the Inova Health System in the U.S. This important new tumor processing method promises the potential for significant improvements in the clinical management of most solid tumor cancers. Dr. Conrads’ novel workflow is the basis of Pressure BioSciences’ major co-marketing collaboration recently announced with Leica Microsystems (a Danaher company).
“It is clear why we see this award of the PCT MP patent as a critical milestone in securing our pivotal intellectual property around the PCT system, and another important driver toward accelerated adoption of PCT in biological sample preparation markets. We expect to take full advantage of this opportunity and further boost our sales,” Ms. McCloskey said.
Dr. Alexander Lazarev, Pressure BioSciences’ Chief Scientific Officer, added: “This long-anticipated patent is an exciting endorsement of our efforts to transform biological sample preparation. This powerful new dimension to our patent protected portfolio should help us to secure and accelerate the growth of our business.”
For more information, visit the company’s website at www.PressureBioSciences.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Pressure BioSciences develops and sells pressure-based instruments and consumables to the global life sciences, food and beverage, and other large research markets
- Their products are based on three key technology platforms, led by their proprietary Pressure Cycling Technology (“PCT”)
- The award of the PCT MicroPestle (“MP”) patent moves Pressure BioSciences even closer to entering the clinical diagnostics market, which is exponentially larger than the research products market where the Company currently transacts business
- The Company utilizes a “razor: razor blade” business model, and the PCT MP is the Company’s most important and popular consumable to date
- PBI has seen revenue from consumables steadily increase in recent years and double in just four years. The new patent provides greater security for its business model as well as potential for more explosive growth
- Recent publications from highly regarded scientists in Australia, China, and the U.S., cite the important use of PCT and the PCT MP in critical areas of scientific research, including cancer and COVID-19 research
Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide Life Sciences and other industries, has been awarded a pivotal U.S. patent for “Sample Preparation Devices and Methods” (http://nnw.fm/fIYe6).
With this new patent, the Company continues to expand its already significant intellectual property ownership, which now includes 25 issued patents.
Pressure BioSciences’ unique pressure cycling technology (“PCT”) systems are comprised of two major, interdependent components: the pressure cycling instrument and the consumable that contains and delivers the cycled pressure to the sample. The newly patented PCT MicroPestle (“MP”) is a critical addition to the Company’s impressive instruments and consumables product line.
The PCT MP is the Company’s most important and popular consumable to date, having a unique construction that seals and protects the sample while flexing to transfer immense pressures to the important samples being processed inside the MP tube. This, in turn, facilitates homogenization and precise physical and chemical preparation of biological samples, sometimes very small and hard-to-process specimens such as needle biopsies, small suspensions of cells, and laser micro-dissected tissue sections.
The PCT MicroPestle is designed with inert fluoropolymer material, which maintains stability for the sample as it experiences significant temperature fluctuations. The PCT MP also provides powerful resistance to aggressive chemicals. Extremely low surface binding characteristics enable the PCT MP to preserve and maximize the availability of each sample’s precious molecules, which often include important biomarkers for disease diagnosis or critical prognostic decisions regarding treatment selection and guidance.
Recent publications cite the use of PCT and the PCT MP in cancer and COVID-19 research, citing the use of the Company’s products in their studies to develop better methods for the detection, prevention, and cure of infectious diseases.
Prospective Financial Impact of the New Patent
With the PCT MP, Pressure BioSciences inches all that much closer to entering the clinical market, which has exponentially larger potential than the research market, where the Company currently transacts business. With just one proven clinical application of PCT and the PCT MP, Pressure BioSciences will have enormous potential for revenue.
PCT instruments tend to heavily impact revenue up front, while consumables continue to provide revenue potential throughout the life of the instrument. Pressure BioSciences has seen revenue from consumables steadily increase in recent years and double in just the past four years, from $150K in 2015 to $260K in 2017 and then $300K in 2019. The new patent provides even more security for this kind of growth and potential for more explosive growth.
Several high-profile labs in pharma, biotech, government, and academia routinely use the PCT MP. Publications about the capabilities of PCT MP are making their way into circulation and garnering attention. This is particularly true for the processing of minute cancer biopsy tissues and other small specimens where the options for a high-quality processing method are few and far between.
Worldwide Customer Demand
According to Ms. Roxana McCloskey, Pressure BioSciences’ Global Director of Sales and Marketing, the PCT MP is already used in prominent studies such as the one conducted by Professor Phil Robinson and his team at the Children’s Medical Research Institute in Australia (processing 70,000 tumor samples, looking for prognostic and diagnostic markers in cancer) and the one run by Dr. Tiannan Guo and his team at Westlake University in China (studying thyroid cancer and COVID-19).
The PCT MP is also a critical part of the innovative laser microdissection tumor processing workflow developed by Dr. Tom Conrads of the Inova Health System in the U.S. This important new tumor processing method promises the potential for significant improvements in the clinical management of most solid tumor cancers. Dr. Conrads’ novel workflow is the basis of Pressure BioSciences’ major co-marketing collaboration recently announced with Leica Microsystems (a Danaher company).
“It is clear why we see this award of the PCT MP patent as a critical milestone in securing our pivotal intellectual property around the PCT system, and another important driver toward accelerated adoption of PCT in biological sample preparation markets. We expect to take full advantage of this opportunity and further boost our sales,” Ms. McCloskey said.
Dr. Alexander Lazarev, Pressure BioSciences’ Chief Scientific Officer, added: “This long-anticipated patent is an exciting endorsement of our efforts to transform biological sample preparation. This powerful new dimension to our patent protected portfolio should help us to secure and accelerate the growth of our business.”
For more information, visit the company’s website at www.PressureBioSciences.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼